1. Home
  2. EOCN vs CVKD Comparison

EOCN vs CVKD Comparison

Compare EOCN & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EOCN

Eocene Ltd. Ordinary Shares

N/A

Current Price

$1.84

Market Cap

2.9M

Sector

Health Care

ML Signal

N/A

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

SELL

Current Price

$1.68

Market Cap

3.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
EOCN
CVKD
Founded
2000
2022
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
3.4M
IPO Year
2013
2022

Fundamental Metrics

Financial Performance
Metric
EOCN
CVKD
Price
$1.84
$1.68
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $14.00
AVG Volume (30 Days)
8.9K
★ 111.2K
Earning Date
12-04-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 23.94
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.79
$0.82
52 Week High
$3.80
$12.50

Technical Indicators

Market Signals
Indicator
EOCN
CVKD
Relative Strength Index (RSI) 22.75 63.83
Support Level N/A $0.88
Resistance Level $2.98 $2.23
Average True Range (ATR) 0.30 0.21
MACD -0.08 0.06
Stochastic Oscillator 1.64 72.42

Price Performance

Historical Comparison
EOCN
CVKD

About EOCN Eocene Ltd. Ordinary Shares

Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Share on Social Networks: